GREENWOOD VILLAGE, CO, Feb. 06, 2018 (GLOBE NEWSWIRE) — Helix TCS, Inc. (OTCQB: HLIX), along with its investment partner Rose Capital, acquired all of the outstanding preferred stock of Bio-Tech Medical Software, Inc. (or BioTrackTHC). This investment represents approximately 18.5% of BioTrackTHC’s outstanding capital stock, on an as-converted to common basis. In addition, Helix CEO Zac Venegas will join BioTrackTHC’s board.
Helix TCS Inc. and Rose Capital Acquire 100% of the Preferred Stock of BioTrackTHC
![](https://rosecapital.com/wp-content/uploads/2018/02/rosecapital-news-12.png)